3-Aminopyrrolidinone Farnesyltransferase Inhibitors: Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell PotencyIan M. Bell, C. Blair Zartman, Michelle Ellis-Hutchings et al.|Journal of Medicinal Chemistry|2002Cited by 86
Potent <i>N</i>-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion ChannelMark T. Bilodeau, George D. Hartman, Adrienne E. Balitza et al.|Journal of Medicinal Chemistry|2004Cited by 60
Identification and Characterization of 4-Methylbenzyl 4-[(Pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an Orally Bioavailable, Brain Penetrant NR2B Selective<i>N</i>-Methyl-<scp>d</scp>-Aspartate Receptor AntagonistNigel J. Liverton, Kenneth S. Koblan, Rodney A. Bednar et al.|Journal of Medicinal Chemistry|2007Cited by 45
Design and Biological Activity of (<i>S</i>)-4-(5-{[1-(3-Chlorobenzyl)-2- oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-Aminopyrrolidinone Farnesyltransferase Inhibitor with Excellent Cell PotencyIan M. Bell, Theresa M. Williams, Steven N. Gallicchio et al.|Journal of Medicinal Chemistry|2001Cited by 43
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinaseJohn T. Sisko, George D. Hartman, Thomas J. Tucker et al.|Bioorganic & Medicinal Chemistry Letters|2005Cited by 35